Clay Siegall, the Titan of Targeted Drugs Therapies
Clay Siegall is the founder and Chief Executive of Seattle Genetics, a biotechnology firm started in 1998. This company develops therapy drugs for ailments like cancer that are yet to have improvements in mortality rates. Dr. Siegall trained as a zoologist at The University of Maryland then obtained his doctorate at George Washington University.
With Siegall at the helm, Seattle Genetics has catapulted to the top of the industry as seen with notable achievements like developing the inaugural antibody-drug conjugate approved by the FDA. The firm has also developed an upwards of 20 targeted therapy drugs and has forged partnerships with leading pharmaceutical manufacturers like Pfizer and Bayer.
Seattle Genetics is now an indomitable player in the cancer research world but Dr. Siegall isn’t stopping there. The firm is expanding its drug portfolio and is poised to join the ranks of top industry leaders in the near future. Siegall is eager to replace chemo treatments of cancer with more effective targeted drugs that will dramatically increase the chances of beating cancer.
As with all great stories, personal tragedy is a driving factor. Between 19 to 24 years, Siegall watched his father battle cancer and eventually lose the fight. He was devastated and wished to enhance oncology tools. To this end, he sought employment at the Pharmaceutical Research Institute of Bristol-Myers Squibb. During his tenure, Siegall learned the intricacies of the trade and running a business.
Besides the lucrative nature of the business trading proprietary drugs and production partnerships, Siegall is driven by a passion to help patients whose fate is seemingly doomed. He is keen to leverage technology and science to develop targeted drugs that will end the misery of patients the world over. He also reckons that drug manufacturing is risky and comes with a hefty price tag especially with respect to getting FDA approval. Siegall notes that recruiting a robust team in sales, legal and other departments is a prerequisite to excelling.
Clay Siegall is unstoppable and will continue to delve into cancer research until viable alternatives are found. He is keen to explore partnerships with innovators and industry behemoths to bring his goals to fruition.